Orkambi 100 mg (Lumacaftor TABLET) 100 MG

Orkambi 100 MG tablets contain lumacaftor, a medication used to treat cystic fibrosis. This oral medication is designed to improve lung function and reduce symptoms associated with the condition.

Strength

100 MG

Pack Size

28/112

Manufacturer / TM Owner

VERTEX PHARMACEUTICALS (CANADA) INCORPORATED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Orkambi 100 MG tablets are primarily used in the management of cystic fibrosis. Lumacaftor, the active ingredient, works to enhance the function of a protein affected by the genetic condition, potentially improving respiratory health. This medication is often prescribed as part of a comprehensive treatment plan for cystic fibrosis patients.

Side Effects

Common effects of Orkambi 100 MG tablets may include respiratory improvements, such as better lung function and reduced symptoms like coughing and shortness of breath. Some individuals may experience side effects, which can vary in severity and frequency.

Precautions & Warnings

Orkambi 100 MG tablets should be handled with care. It is important to follow the advice of a healthcare provider regarding administration and monitoring. Patients should be aware of potential side effects and discuss any concerns with their healthcare provider.

Avoid Interactions

Orkambi 100 MG tablets may interact with other medications, including those metabolized by the liver. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain foods may also affect how this medication works.

Frequently Asked Questions

Orkambi 100 MG tablets are used to manage cystic fibrosis by improving lung function and reducing symptoms.

Orkambi 100 MG tablets are taken orally, typically as prescribed by a healthcare provider.

Common side effects may include respiratory improvements and potential side effects that vary among individuals.

It is important to consult a healthcare provider before taking Orkambi 100 MG with other medications to avoid potential interactions.

Precautions include following healthcare provider instructions, monitoring for side effects, and discussing any concerns with a healthcare professional.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.